Back to Search
Start Over
Figure S1 from In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- In vivo efficacy of tesevatinib 70 mg/kg in PDX GBM models
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....1c19b33dcf20878483aa29e0d9652653
- Full Text :
- https://doi.org/10.1158/1535-7163.22522416.v1